Pharmaxis Awarded Two ARC Linkage Grants for Fibrotic Research
Release Date: 05/07/2013 12:00am
Pharmaceutical company Pharmaxis (ASX:PXS) today announced that two of its research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Council (ARC) Linkage Projects scheme.
Leading Australian renal physician Professor Carol Pollock is heading an investigation of the utility of Pharmaxis compound PXS-4728A in treating renal fibrosis, while in a separate project Associate Professors Paul Young and Daniela Traini, and Dr Brian Oliver will work on developing advanced inhalation technology to deliver Pharmaxis’ compounds to underlying fibrotic cells in the lung.
The ARC Scheme will provide funding of $405,646 and $370,000 for the two projects respectively, over three years which will match expenditure by Pharmaxis.
Categories: News and Media